Navigation Links
MindUp (HIRU) Patents in the World Patent Database
Date:2/10/2010

BELGRADE, Serbia, Feb. 10 /PRNewswire-FirstCall/ - Hiru Corporation (HIRU; www.hirucorporation.com) and its European subsidiary MindUp BioResearch (www.mindupbioresearch.com) want to share publicly available information about the MindUp and Sabera Ruzdijic's patents. Dr. Sabera Ruzdijic is the project and team manager of the MindUp BioResearch cancer project. The other team leaders in MindUp Research project are Dr. Nikola Tanic, Dr. Milica Pesicand and Dr. Jasna Bankovic.

The following links lead to the European Patent Office Database and patents awarded to Dr. Sabera Ruzdijic:

Link # 1 shows search results for "Sabera Ruzdijic" entered into European Patent Office's "Advanced Search", in the "Inventor(s)" field;

http://v3.espacenet.com/searchResults?DB=EPODOC&submitted=true&locale=en_EP&IN=Sabera%20Ruzdijic&ST=advanced&compact=false

Link # 2 shows the "Patent Family", patents affiliated and similar to the MindUp Research patents,

http://v3.espacenet.com/searchResults?DB=EPODOC&submitted=true&locale=en_EP&IN=Sabera%20Ruzdijic&ST=advanced&compact=false

The patent invention relates to the field of cancer therapy, and more particularly to the use of antisense oligonucleotides to decrease up-regulated genes involved in lung and melanoma cancers. Treatment has the ability to reduce gene expression in lung cancer by more than 50%.

More updates will be released by the company shortly.

To be included in HIRU's email database for press releases and industry updates, please subscribe at or opt in with your email address at this link http://www.minamargroup.com/updates/.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hiru Corporation that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hiru Corporation cautions you that any forward-looking information provided by or on behalf of Hiru Corporation is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hiru Corporation's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hiru Corporation's control. In addition to those discussed in Hiru Corporation's press releases, public filings, and statements by Hiru Corporation's management, including, but not limited to, Hiru Corporation's estimate of the sufficiency of its existing capital resources, Hiru Corporation's ability to raise additional capital to fund future operations, Hiru Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hiru Corporation's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hiru Corporation does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: Hiru Corporation, www.minamargroup.net/helpdesk, Ph (647) 426-1640

SOURCE Hiru Corporation


'/>"/>
SOURCE Hiru Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Hard To Treat Diseases (HTDS) Finalizes Sale Of Its MindUp BioResearch Division To (HIRU)
2. Hard to treat Diseases (HTDS) To Sell Its MindUp BioResearch Division
3. Slavica Bio Chem MindUp Cancer Project (HTDS) Research Led To The Identification Of Genes Associated With Lung Cancer Promotion And Progression
4. Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock
5. Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East
6. U.S. District Court Upholds Validity of Lillys Evista Patents Through 2014
7. GENova Biotherapeutics signs LOI with Korean university for stem cell research and patents sharing
8. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
9. Warner Chilcott Files New Lawsuit for Infringement of LOESTRIN(R) 24 FE and FEMCON(R) FE Patents
10. Isis Receives Notice of Allowance That Expands the Scope of Key RNA Therapeutic Patents for Single-Stranded RNAi Technology
11. Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... EDWARDSVILLE, Ill. (PRWEB) , ... ... ... University Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and ... educated healthcare professionals on guideline updates for the primary prevention of cardiovascular ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 AVACEN Medical , Inc. (AVACEN) ... their  2017 New Product Innovation Award for Its fibromyalgia ... and secondary medical device market research by Frost & Sullivan,s ... OTC, drug-free pain relief product, the AVACEN 100, offers a ... fibromyalgia widespread pain. ...
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
Breaking Medicine Technology: